ATE418562T1 - Ctl epitope des epstein-barr virus - Google Patents

Ctl epitope des epstein-barr virus

Info

Publication number
ATE418562T1
ATE418562T1 AT98931834T AT98931834T ATE418562T1 AT E418562 T1 ATE418562 T1 AT E418562T1 AT 98931834 T AT98931834 T AT 98931834T AT 98931834 T AT98931834 T AT 98931834T AT E418562 T1 ATE418562 T1 AT E418562T1
Authority
AT
Austria
Prior art keywords
seq
ebv
epstein
barr virus
ctl epitopes
Prior art date
Application number
AT98931834T
Other languages
English (en)
Inventor
Scott Burrows
Rajiv Khanna
Original Assignee
Queensland Inst Med Res
Commw Scient Ind Res Org
Univ Melbourne
Inst Medical W & E Hall
Csl Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queensland Inst Med Res, Commw Scient Ind Res Org, Univ Melbourne, Inst Medical W & E Hall, Csl Ltd filed Critical Queensland Inst Med Res
Application granted granted Critical
Publication of ATE418562T1 publication Critical patent/ATE418562T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98931834T 1997-07-10 1998-07-10 Ctl epitope des epstein-barr virus ATE418562T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPO7841A AUPO784197A0 (en) 1997-07-10 1997-07-10 Treatment of nasopharyngeal carcinoma

Publications (1)

Publication Number Publication Date
ATE418562T1 true ATE418562T1 (de) 2009-01-15

Family

ID=3802132

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931834T ATE418562T1 (de) 1997-07-10 1998-07-10 Ctl epitope des epstein-barr virus

Country Status (11)

Country Link
US (2) US6723695B1 (de)
EP (1) EP1003773B1 (de)
JP (1) JP2001509514A (de)
CN (1) CN100526331C (de)
AT (1) ATE418562T1 (de)
AU (1) AUPO784197A0 (de)
CA (1) CA2294732A1 (de)
DE (1) DE69840383D1 (de)
NZ (1) NZ501944A (de)
WO (1) WO1999002550A1 (de)
ZA (1) ZA986084B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003514871A (ja) 1999-11-24 2003-04-22 オクラホマ メディカル リサーチ ファウンデーション 潜伏ウイルス感染についてのアッセイおよび治療
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
US20070048329A1 (en) * 2002-11-07 2007-03-01 Rajiv Khanna Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
WO2004067032A2 (en) 2003-01-24 2004-08-12 University Of Massachusetts Medical Center Identification of gene sequences and proteins involved in vaccinia virus dominant t cell epitopes
US8067535B2 (en) 2003-01-24 2011-11-29 The University Of Massachusetts Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
FR2850384A1 (fr) * 2003-01-28 2004-07-30 Centre Nat Rech Scient Antigenes mimant les domaines extracellulaires de proteines membranaires de type iii issues de microorganismes intracellulaires pathogenes, anticorps conformationnels derives, et leurs applications
US8451808B2 (en) 2006-02-18 2013-05-28 Intel Corporation Techniques for 40 megahertz (MHz) channel switching
EP1826264A1 (de) * 2006-02-24 2007-08-29 Deutsches Primatenzentrum GmbH Primatmodell für Orthopoxvirus-Infektionen
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
CN102812043A (zh) * 2009-11-19 2012-12-05 新加坡国立大学 用于制备t细胞受体样单克隆抗体的方法及其用途
EP2611905A4 (de) * 2010-09-01 2014-02-12 Baylor College Medicine Ebv-spezifische zytotoxische t-lymphozyten zur behandlung des lokoregionären nasopharynxkarzinoms (npc)
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
KR101749195B1 (ko) 2011-12-12 2017-06-20 셀 메디카 리미티드 T 세포들을 증식시키는 방법
ES2748652T3 (es) 2012-02-09 2020-03-17 Baylor College Medicine Mezclas pep para generar CTL multivíricos con amplia especificidad
WO2013139789A1 (en) * 2012-03-19 2013-09-26 Deutsches Krebsforschungszentrum B-cell receptor complex binding proteins containing t-cell epitopes
EP2909238A4 (de) 2012-10-19 2016-11-30 Queensland Inst Med Res Verbesserte immuntherapie gegen das humane herpesvirus
EP3604271A1 (de) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptide für aminosäure- und peptidkonjugate und konjugationsverfahren
EP3102590B1 (de) * 2014-02-07 2019-08-07 Valorisation-HSJ, Limited Partnership Antigene epitope aus ebv gp350/220 und verwendungen davon
KR102730367B1 (ko) 2014-04-15 2024-11-15 그리피스 유니버시티 그룹 a 스트렙토코쿠스 백신
AU2015343239B2 (en) 2014-11-05 2021-06-03 Memorial Sloan Kettering Cancer Center Methods of selecting T cell line and donor thereof for adoptive cellular therapy
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
NZ736675A (en) * 2015-05-12 2023-03-31 Memorial Sloan Kettering Cancer Center Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
KR101794304B1 (ko) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 Ｅｂｖ 항원 특이 ｔ―세포 수용체 및 이의 용도
EP3350600A4 (de) 2015-09-18 2019-04-17 Baylor College of Medicine Unterscheidung eines immunogenen antigens von einem pathogen und korrelation mit klinischer wirksamkeit
ES2795440T3 (es) * 2015-12-04 2020-11-23 Agency Science Tech & Res Correlaciones clínicas de la eficacia de la inmunoterapia
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
IL262989B2 (en) * 2016-05-25 2025-08-01 Council Queensland Inst Medical Res Methods for treating autoimmune disease using allogeneic T cells
ES2940418T3 (es) 2016-09-02 2023-05-08 Univ James Cook Péptido para la cicatrización de heridas
AU2017330379B2 (en) 2016-09-23 2023-07-13 Memorial Sloan Kettering Cancer Center Generation and use in adoptive immunotherapy of stem cell-like memory T cells
CN106397574A (zh) * 2016-10-21 2017-02-15 上海交通大学医学院附属新华医院 抗原表位肽及其应用
JP7123921B2 (ja) 2016-11-09 2022-08-23 グリフィス・ユニバーシティ サブチラーゼサイトトキシンｂサブユニット変異体
CN107267481A (zh) * 2017-05-09 2017-10-20 上海交通大学医学院附属新华医院 Cdk5抗原表位肽及其应用
US12338458B2 (en) 2017-05-25 2025-06-24 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
NL2023863B1 (en) 2019-09-20 2021-05-25 Univ Griffith Protein particles and uses thereof
MX2022006299A (es) 2019-11-25 2023-01-19 Univ Griffith Proteína inmunogénica contra una infección gonocócica.
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
AU2021356478A1 (en) * 2020-10-07 2023-06-01 The Council Of The Queensland Institute Of Medical Research Herpesvirus polyepitope vaccines
US20240325539A1 (en) 2020-10-20 2024-10-03 The Chancellor, Masters And Scholars Of The University Of Oxford Methods and compositions for treating epstein barr virus-associated cancer
CN115786509A (zh) * 2022-10-21 2023-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种鼻咽癌患病风险预测试剂盒

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173254B1 (de) 1984-08-23 1991-07-24 Hans Joachim Wolf DNA-Sequenzen des EBV-Genoms, rekombinante DNA-Moleküle, Verfahren zur Herstellung von EBV-verwandten Antigenen sowie diagnostische Zusammensetzungen und pharmazeutische Zusammensetzungen, die die genannten Antigene enthalten
US4879213A (en) 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
AUPM446594A0 (en) * 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
AU1942595A (en) * 1994-03-16 1995-10-03 Csl Limited Cytotoxic t-cell epitopes
MY114769A (en) * 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
AU3072395A (en) * 1994-07-27 1996-02-22 Csl Limited Polyepitope vaccines
EP0769963A4 (de) 1994-07-27 1999-07-28 Commw Scient Ind Res Org Polyepitope impfstoffe
GB9501300D0 (en) 1995-01-24 1995-03-15 Boughton Brian J Peptides which inhibit viruses
AU712364B2 (en) * 1996-05-24 1999-11-04 Council Of The Queensland Institute Of Medical Research, The EBV CTL epitopes
AUPO007396A0 (en) * 1996-05-24 1996-06-20 Csl Limited Ebv ctl epitopes

Also Published As

Publication number Publication date
EP1003773B1 (de) 2008-12-24
US6723695B1 (en) 2004-04-20
WO1999002550A8 (en) 2000-06-15
US20030152582A1 (en) 2003-08-14
DE69840383D1 (de) 2009-02-05
AUPO784197A0 (en) 1997-08-07
CN100526331C (zh) 2009-08-12
CA2294732A1 (en) 1999-01-21
CN1269804A (zh) 2000-10-11
NZ501944A (en) 2001-11-30
EP1003773A4 (de) 2002-08-07
JP2001509514A (ja) 2001-07-24
ZA986084B (en) 1999-01-26
WO1999002550A1 (en) 1999-01-21
EP1003773A1 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
ATE418562T1 (de) Ctl epitope des epstein-barr virus
NZ335612A (en) A composition containing cytotoxic specificT-cell epitopes being either Rev and/or Tat proteins from HIV virus for prevention and treatment of human immunodeficiency virus (HIV) infection
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
BR9814487A (pt) "vacina"
FR12C0004I1 (de)
IL123506A0 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP0726758A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozythen gerichetetgegen das hepatitis b-virus
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
GB2301591A (en) Cytotoxic T-cell epitopes
EP0687182A4 (de) Peptide zum induzieren einer antwort der zytotoxischen t-lymphozyten gerichtet gegen das hepatitis b virus
EP1173204A4 (de) Humane cd80-mutante und zusammensetzungen und methoden zu deren herstellung und verwendung
HUP9801266A2 (hu) Multimer, rekombináns ureázvakcina
GB2332907B (en) EBV CTL Epitopes
NO920331D0 (no) Biologisk preparat samt bruk derav
AU5423898A (en) Therapeutic applications of antigens or epitopes associated with impaired cellular peptide processing, e.g. expressed on rma-s cells transfected with a b7-1 gene
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
OA09037A (en) Prevention and treatement of retroviral disease.
SE9600436D0 (sv) Vaccine against hantavirus
AP2001002354A0 (en) Use of antibodies recognizing the interleukin-2 receptor in the prevention and /or treatment of infections by the AIDS viruses.
NZ316110A (en) vaccine containing an antigen from H. Influenzae and an antigen from influenza virus
ATE349532T1 (de) Zytotoxisches t-zellepitop des papillomavirus l1- proteins und seine verwendung in diagnostik und therapie
WO2000024876A3 (en) Spumavirus isolated from humans

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties